Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod
20 déc. 2021 07h00 HE
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 nov. 2021 16h30 HE
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
12 nov. 2021 07h05 HE
|
Checkmate Pharmaceuticals Inc.
Alan Fuhrman appointed interim President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing Clinical data readouts anticipated in 2022 ...
Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
12 nov. 2021 07h01 HE
|
Checkmate Pharmaceuticals Inc.
Vidutolimod in combination with pembrolizumab demonstrated promising clinical activity in patients with PD-1 blockade-refractory melanoma with an ORR of 23.5% per RECIST v1.1 Vidutolimod also...
Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
11 nov. 2021 16h30 HE
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
01 nov. 2021 08h01 HE
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary...
Checkmate Pharmaceuticals Announces CEO Transition
27 oct. 2021 16h30 HE
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)
20 oct. 2021 16h30 HE
|
Checkmate Pharmaceuticals Inc.
Live presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET Featured speakers include Jason Luke, M.D., FACP and Art Krieg, M.D. CAMBRIDGE,...
Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
14 sept. 2021 16h30 HE
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 07h00 HE
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...